Life with TGCT
Emactuzumab
About
Media

Expanded Access

Home
Life with TGCT
Emactuzumab
Who we are
Meet the team
Contact
Join us
Events
Publications
Press Releases
Expanded Access
Privacy Policy
Terms & Conditions

Home
Media
Publications
ESMO Primary Analysis of TANGENT

ESMO Primary Analysis of TANGENT

22 October 2026

Phase 3 Randomised Trial Evaluating the Safety and Efficacy of Emactuzumab in Patients With Tenosynovial Giant Cell Tumours

Life with TGCT
Emactuzumab
Who we are
Meet the team
Contact
Join us
Events

Publications
Press Releases
Expanded Access
Terms and Conditions
Privacy Policy

SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, an investigational, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

© Copyright 2026 SynOx Therapeutics. All rights reserved.

You are about to leave our website

We are not responsible for the content. Do you want to proceed?